Vergent Bioscience to present phase 2 clinical data for VGT-309 at IASLC 2023 World Conference on Lung Cancer
Vergent Bioscience and its wholly owned subsidiary Vergent Bioscience Australia Pty Ltd, announced that new clinical data from a Phase 2 study of the company’s investigational agent VGT-309 will be presented at the 2023 World Conference on Lung Cancer (#WCLC23) hosted by the International Association for the Study of Lung Cancer (IASLC), taking place September 9-12, 2023, in Singapore.
Early Phase 1 and 2 clinical trials evaluating VGT-309 in lung cancer yielded compelling safety and efficacy data that support the agent’s ability to help surgeons see difficult-to-find or previously undetected tumors in real-time, ensuring all tumor tissue is removed during minimally invasive (MIS) and robotic-assisted surgical procedures.
Following are details about the VGT-309 presentation at the 2023 WCLC:
Title: Results from a Phase II trial of a Tumor-Activated Fluorescent Molecule for the Intra-Operative Identification of Lung Cancer
Presenter: Professor Gavin M. Wright, Ph.D., director of Surgical Oncology, St. Vincent’s Hospital, Melbourne, Australia
Abstract/Session: #844; MA11.06 – New Technology and Innovations in Early-Stage Lung Cancer
Date/Time: 2:30 - 3:30 PM Singapore/2:30 – 3:30 AM ET, September 11, 2023
Location: Suntec Singapore Convention & Exhibition Centre, Room 405C
